Trevi Therapeutics (TRVI) Free Cash Flow (2018 - 2026)
Trevi Therapeutics (TRVI) posted quarterly Free Cash Flow of -$16.8 million for Q1 2026, down 24.59% year-over-year from -$22.3 million in Q1 2025, and down 120.04% quarter-over-quarter from -$7.6 million in Q4 2025.
Trevi Therapeutics (TRVI) Free Cash Flow (2018 - 2026) Analysis & Trends
Trevi Therapeutics' Free Cash Flow history runs 9 years deep, the most recent figure standing at -$16.8 million for Q1 2026.
- In Q1 2026, Free Cash Flow fell 24.59% year-over-year to -$16.8 million; the TTM figure through Mar 2026 stood at -$45.4 million (down 10.04% YoY), while the FY2025 annual figure was -$42.1 million, down 9.95% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$16.8 million, down from -$7.6 million in the prior quarter.
- The five-year high for Free Cash Flow was -$6.2 million in Q2 2022, with the low at -$16.8 million in Q1 2026.
- The 5-year median for Free Cash Flow is -$8.7 million (2024), against an average of -$9.3 million.
- The sharpest annual moves came in 2022 and 2023: Free Cash Flow rose 21.8% in 2022, then plunged 60.54% in 2023.
- Trevi Therapeutics' Free Cash Flow stood at -$6.4 million in 2022, then advanced by 1.02% to -$6.4 million in 2023, then plunged by 49.77% to -$9.6 million in 2024, then increased by 20.15% to -$7.6 million in 2025, then sank by 120.04% to -$16.8 million in 2026.
- Business Quant data shows TRVI's Free Cash Flow at -$16.8 million in Q1 2026, -$7.6 million in Q4 2025, and -$10.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Trevi Therapeutics | 2.63 Bn | 2.63 Bn | - | -17.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -17.55 Mn |
| Jun 30, 2026 | -17.55 Mn |
| Mar 31, 2026 | -16.79 Mn |
| Mar 31, 2026 | -16.79 Mn |
| Dec 31, 2025 | -7.63 Mn |
| Dec 31, 2025 | -7.63 Mn |
| Sep 30, 2025 | -10.89 Mn |
| Sep 30, 2025 | -10.89 Mn |
| Jun 30, 2025 | -10.10 Mn |
| Jun 30, 2025 | -10.10 Mn |
| Mar 31, 2025 | -13.48 Mn |
| Mar 31, 2025 | -13.48 Mn |
| Dec 31, 2024 | -9.56 Mn |
| Dec 31, 2024 | -9.56 Mn |
| Sep 30, 2024 | -9.56 Mn |
| Sep 30, 2024 | -9.56 Mn |
| Jun 30, 2024 | -8.68 Mn |
| Jun 30, 2024 | -8.68 Mn |
| Mar 31, 2024 | -10.47 Mn |
| Mar 31, 2024 | -10.47 Mn |